AKT1 and cancer: Further advances have led to the development of dual PI3K-mTOR inhibitors such as GDC-0980, which are hypothesized to have more potent anti-cancer effects due to their ability to circumvent feedback stimulation of PI3K-AKT-mTOR signalling.